SEC Form 4/A · accession 0001209191-17-057661
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Oct 12, 2017
Accepted (ET)
Oct 20, 2017 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 12, 2017 | M | 380,000 | $14.2495 | A | 708,001 | D | |
| Common StockF3 | Oct 12, 2017 | S | 380,000 | $14.2495 | D | 328,001 | D | |
| Common StockF4 | Oct 13, 2017 | M | 22,160 | $14.7503 | A | 350,161 | D | |
| Common StockF5 | Oct 13, 2017 | S | 22,160 | $14.7503 | D | 328,001 | D | |
| Common Stock | Oct 16, 2017 | M | 47,135 | $14.75 | A | 375,136 | D | |
| Common Stock | Oct 16, 2017 | S | 47,135 | $14.75 | D | 328,001 | D | |
| Common Stock | holding | — | — | — | 64,895 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $6.45 | Oct 12, 2017 | M | 5,783 | D | Feb 15, 2016 | Feb 15, 2022 | Common Stock | 5,783 | 131,024 | D |
| Stock Options (right to buy) | $4.38 | Oct 12, 2017 | M | 13,622 | D | Jun 4, 2016 | Jun 4, 2022 | Common Stock | 13,622 | 136,378 | D |
| Stock Options (right to buy) | $3.53 | Oct 12, 2017 | M | 3,462 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 3,462 | 161,538 | D |
| Stock Options (right to buy) | $2.52 | Oct 12, 2017 | M | 165,000 | D | Jun 18, 2017 | Jun 18, 2023 | Common Stock | 165,000 | 0 | D |
| Stock Options (right to buy) | $3.19 | Oct 12, 2017 | M | 192,133 | D | Jan 3, 2015 | Jan 3, 2024 | Common Stock | 192,133 | 20,972 | D |
| Stock Options (right to buy) | $3.53 | Oct 13, 2017 | M | 22,160 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 22,160 | 139,378 | D |
| Stock Options (right to buy) | $3.53 | Oct 16, 2017 | M | 47,135 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 47,135 | 92,243 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F5This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Remarks
This Form 4 amendment corrects the reporting person's Remarks from the originally filed Form 4. The Remarks should read as follows: Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. The total shares sold represented less than 14% of Mr. Crowley's holdings of securities of the company and after these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares.